New prognostic markers in acute myeloid leukemia: perspective from the clinic.
about
Evaluating biomarkers to model cancer risk post cosmic ray exposureClass III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisDo AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Age-specific distributions of cytogenetic subgroups of acute myeloid leukemia: data analysis in a Chinese population.Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemiaCapillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia.Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary reportPhotocleavable peptide-oligonucleotide conjugates for protein kinase assays by MALDI-TOF MSSLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro studyTargeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic LeukemiaAnalyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays.Prediction model for mortality after intracranial hemorrhage in patients with leukemiaSerum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemiaLow Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland.Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia.JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.miRNAs in acute myeloid leukemia.Current findings for recurring mutations in acute myeloid leukemiaNew agents for acute myeloid leukemia: is it time for targeted therapies?Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Selective inhibitors of nuclear export (SINE) in hematological malignancies.Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk GroupsDNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Clinical significance of reduced SFRP1 expression in acute myeloid leukemia.LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data.MicroRNA in Myelopoiesis and Myeloid Disorders
P2860
Q26747120-0EF99778-C240-4406-ADF6-078938B13B05Q26797245-D0E7E1AB-18E8-48AD-9BDA-9DC3C1512BE1Q27851686-3746FE62-0BFD-4247-8A52-08AFD1F6C045Q27853009-985CD3AF-AF81-433D-839B-1D13923646E5Q30582619-112846CA-6168-4DE5-BDFC-4A3E7FC7EF2FQ33598706-28EB165D-0F11-4357-8615-C05B59E15ED4Q33841929-5361AEB5-43FC-40FA-B846-8AC6A7C7B3D5Q34226754-74859B38-34E4-42A6-AC6C-2A076B335C26Q34330361-71D0052A-1841-46BD-906E-F03516D5809AQ34528361-7BCB48B4-FFF0-40BC-B1C1-F481C4407632Q35750567-836F8B92-1D6B-4D15-AB7B-EDBC5837C412Q36322508-61FDE240-D423-4535-B3DA-23552815D2E2Q36390565-DBD2FDBB-01E2-48BF-88AC-D7066C899CBBQ36462887-AA70DF5B-24B3-4A4B-8308-AFE2B38DF2CBQ36464554-EBABF4A5-7B64-45F3-B692-E5A341739A06Q36522939-1ADD314A-24E0-43BA-A3C5-30B104B1F7CDQ36582324-9B53DFF2-DACF-4D42-920E-A87869F90D5AQ36862461-AC0639F3-57AF-4479-A32D-8608BBFA9DE0Q37687651-8FDF3F6E-9E08-4644-8F0D-57D944A0D3A1Q37704373-76AD3393-1976-43BE-8D40-FE8EA971D852Q37709531-8991FAF2-5A5E-4C93-B701-56BBC0A54A16Q37932085-82B96CE7-B62D-4AEC-9E48-B0091447A701Q37973135-1760279E-4423-4D0B-84A6-0B4166004850Q38091393-A6694A4D-28A4-4FD6-8DE0-5059AA208BA7Q38368605-F8E92E32-482D-4452-A67D-291CCCB377ADQ38694866-42C60E72-F1D9-4CBF-8104-765F668D2306Q39471968-44D027D5-96E2-4DCC-8F1A-1D9AFCF99B01Q41498838-9D7E0C02-1448-461D-82D8-0F2F9BD06BD6Q41595632-3F02C291-16D4-421B-9662-5F3363F8A154Q41973082-87786AF2-6D43-416E-BB0C-9F3C584CE77FQ41983363-99FA5DF7-9ADA-4024-8804-22C5F7CE1CC9Q42361215-1B9F89B1-DE61-4DD8-B929-97313A8F691BQ44602971-68941761-E4B7-40F0-A327-56FCE458C35FQ45847205-012487FF-7796-4E7D-8F06-37B3F505CE0FQ47137275-7DA3E8A5-8583-4B01-83A2-578CB45FF630Q48219674-B0FD36B2-E1EF-461C-98E7-047B2755C005Q49181559-3A6D356A-4B82-4F1E-A299-A98E06870C9DQ55163802-3246B20E-EE96-4E84-A12A-E7D127B101E2Q57589030-4B319130-E084-489C-ACB1-24FAEA79FC18
P2860
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
@en
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
@nl
type
label
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
@en
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
@nl
prefLabel
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
@en
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
@nl
P1476
New prognostic markers in acute myeloid leukemia: perspective from the clinic.
@en
P2093
James M Foran
P356
10.1182/ASHEDUCATION-2010.1.47
P577
2010-01-01T00:00:00Z